Gao X, Peng L, Zhang L, Huang K, et al. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer. J Cancer Res Clin Oncol 2021 Nov 8. pii: 10.1007/s00432-021-03848.
PMID: 34748028